Will the latest drive to create a UK environment that rewards medtech innovation with swift adoption and appropriate reimbursement solve the problems that the industry has been highlighting for a decade or more? The fervent hope is that the mechanisms and support offered in recent government initiatives, including the Accelerated Access Review (AAR), will provide lasting answers and represent more than good intentions, well written.
The Association of British Healthcare Industries (ABHI) has commissioned a report that dissects the AAR, and weighs the value that it offers to UK medtech manufacturers as they seek to secure NHS adoption of products and procedures. (Also see "UK Medtech To Leverage Accelerated Access Opportunity, Regardless Of The 'B' Word" - Medtech Insight, 6 November, 2017
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?